Fujishima Motonobu, Matsuda Hiroshi
Department of Radiology, Kumagaya General Hospital, 4-5-1 Nakanishi, Kumagaya, Saitama, 360-8567, Japan.
Department of Biofunctional Imaging, Fukushima Medical University, 1 Hikariga-oka, Fukushima, 960-1295, Japan.
Neuroimage Rep. 2022 May 21;2(3):100101. doi: 10.1016/j.ynirp.2022.100101. eCollection 2022 Sep.
The magnetic resonance imaging (MRI)-less non-standard pipeline for amyloid positron emission tomography (PET) published by Bourgeat et al., in 2018 calculates Centiloid scale values that are highly consistent with those computed using the standard pipeline. The purpose of this study was to demonstrate that the non-standard pipeline can compute Centiloid scale values in high agreement with the standard pipeline when using different datasets of amyloid PET tracers in our local computer environment. PET images of C-Pittsburgh compound B (C-PiB), F-florbetapir, F-flutemetamol, F-florbetaben, and F-NAV4694 from the calibration dataset were processed using both the standard and non-standard pipelines, and the computed cortical standardized uptake value ratio (SUVr) value was converted to the Centiloid scale value using the method described by Klunk et al., in 2015. The conversion equations from the SUVr to Centiloid scale values for each tracer were obtained during this process. Using these equations, we compared the Centiloid scale values obtained using the standard and non-standard pipelines using the validation datasets of each tracer from the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI), Alzheimer's Disease Neuroimaging Initiative (ADNI), and Australian Imaging Biomarkers and Lifestyle (AIBL). In the calibration datasets, there was high agreement (R > 0.97) and slight bias between the Centiloid scale values calculated by the non-standard and standard pipelines for all tracers. Despite relatively little NAV4694 data in the validation datasets, there was high agreement between the Centiloid scale values calculated using the non-standard and standard pipelines for all tracers. The bias for florbetaben and NAV4694 using the non-standard pipeline was 1.6% underestimation and 3.3% overestimation, respectively; these values were smaller than those reported by Bourgeat et al. Analysis of outliers also suggested that the non-standard pipeline might be vulnerable to anatomical anomalies. Given the slight variance of the Centiloid scale in young controls, flutemetamol and NAV4694 might be suitable tracers for the non-standard pipelines. This study demonstrates the replicability of the non-standard pipelines across computing environments, datasets, scanners, and tracers. When MRI is not available, the non-standard pipeline may provide information to aid in visual assessment of amyloid PET.
布尔热阿特等人于2018年发表的用于淀粉样蛋白正电子发射断层扫描（PET）的无磁共振成像（MRI）的非标准流程计算出的百慕大量表值与使用标准流程计算出的值高度一致。本研究的目的是证明，在我们当地的计算机环境中，当使用不同的淀粉样蛋白PET示踪剂数据集时，非标准流程能够计算出与标准流程高度一致的百慕大量表值。使用标准流程和非标准流程对校准数据集中的C-匹兹堡化合物B（C-PiB）、F-氟比他派、F-氟代甲硫氨酸、F-氟贝他班和F-NAV4694的PET图像进行处理，并使用克伦克等人在2015年描述的方法将计算出的皮质标准化摄取值比率（SUVr）值转换为百慕大量表值。在此过程中获得了每种示踪剂从SUVr到百慕大量表值的转换方程。使用这些方程，我们使用来自日本阿尔茨海默病神经成像计划（J-ADNI）、阿尔茨海默病神经成像计划（ADNI）和澳大利亚成像生物标志物与生活方式（AIBL）的每种示踪剂验证数据集，比较了使用标准流程和非标准流程获得的百慕大量表值。在校准数据集中，所有示踪剂的非标准流程和标准流程计算出的百慕大量表值之间具有高度一致性（R>0.
